SHWB Medical Technology Corporation is a global leading company focused on developing and commercializing neurovascular interventional products for treating stroke.
It develops and produces some of the most reliable and technologically advanced products supported by proven clinical data.
The commercialized product portfolio includes the Coil System, a technically differentiated neuro embolic coil system for treating intracranial aneurysms and other neurovascular abnormalities, the Aspiration Catheters for use in the revascularization of patients with acute ischemic stroke, and the Distal Access Catheter for general intravascular usage including neuro.
The spring coil obtained FDA certification in 2016, CE certification in 2017, and officially entered the international market in early 2018. Products have been sold in more than 30 countries and regions such as the United States, China, the European Union, the United Kingdom, and Chile.
The mechanical release spring coil has been certified by the US FDA, CE and Japan PMDA, and was officially launched in the US in the second half of 2019. It has now entered internationally renowned hospitals such as UCLA, Kaiser, Klinikum Stuttgart, and BHR Hospital.
In terms of registration in China, in 2020, distal access catheters and mechanical release coils were approved for marketing by the National Medical Products Administration of China (NMPA).
5F/6F Aspiration Catheter" received US FDA 510(k) marketing authorization.
In 2022, the "6F suction catheter" was approved by the NMPA in China.